GB Patent

GB9509764D0 — Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids

Assigned to Tillotts Pharma AG · Expires 1995-07-05 · 31y expired

What this patent protects

Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases…

USPTO Abstract

Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).

Drugs covered by this patent

Patent Metadata

Patent number
GB9509764D0
Jurisdiction
GB
Classification
—
Expires
1995-07-05
Drug substance claim
No
Drug product claim
No
Assignee
Tillotts Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.